New research shows that type 2 diabetes (T2D) is linked to an imbalance in the gut microbiome. Over time, people with T2D have lost beneficial bacterial strains that help digest dietary fiber and produce butyrate (a key molecule needed for balancing insulin and glucose levels). Research shows there are 3 components to managing diabetes: diet, exercise and the microbiome. This helps explain why diet and exercise are often not enough to keep blood glucose under control. [1-3, 36]
The important connection between the gut microbiome and T2D has been widely recognized by the American Diabetes Association, Mayo Clinic, Johns Hopkins, and others. [13-15]
Pendulum Glucose Control (PGC) is a synbiotic that contains targeted strains of probiotics (beneficial bacteria) and a prebiotic (food to fuel bacteria) for the dietary management of type 2 diabetes. It is clinically shown to help people with T2D manage A1C and blood glucose spikes. As a medical probiotic, PGC is:
Clinically tested. PGC has been clinically shown to help people with type 2 diabetes (T2D) manage A1C levels and blood sugar spikes. These results were presented at the American Diabetes Association's 79th Scientific Sessions.
Targeted. PGC is designed to provide dietary management of T2D by increasing the gut microbiome's butyrate-producing and mucin-regulating functions. In this way, PGC addresses deficiencies in these functions associated with T2D.
Novel. Our unique, patented formula includes targeted strains discovered through DNA sequencing to meet the specific dietary needs of people with T2D.
In a randomized, double-blinded, placebo controlled, multi-site study, PGC demonstrated statistically significant reductions in A1C and blood sugar spikes (AUC), after 12 weeks of use, compared to placebo, in people with T2D, managed with diet and exercise alone, or, in combination with metformin and/or sulfonylurea.
“We found Pendulum Glucose Control to be safe, well-tolerated, and an effective way to help those living with type 2 diabetes manage their disease,” says Dr. Damaris Vega, endocrinologist, Juno Research LLC.
To review the full study, click here.
*A nutrition study demonstrated significant reduction in A1C and blood glucose spikes in people with type 2 diabetes after 12 weeks of use and compared to placebo. It was randomized, double-blinded, placebo controlled, and across multiple sites in the U.S.
We've partnered with leading researchers at the Mayo Clinic to create the first Mayo Registry for a medical probiotic. The Mayo Clinic has been a leader in advancing microbiome science through the Mayo Microbiome Program. The Mayo Clinic is compiling and reporting results from PGC customers who voluntarily and anonymously share their data. All PGC customers are eligible to participate in this important scientific endeavor.
PGC delivers targeted beneficial bacterial strains to the gut microbiome for people with T2D to help restore lost functionality of metabolizing fiber into butyrate.
Butyrate is a short chain fatty acid critical to digestive health, a healthy metabolism and healthy blood glucose levels. Over 5,000 research studies have shown that butyrate plays several important roles in the gut. It’s a major fuel source for cells lining the large intestine and is involved in improving immunity and reducing inflammation. Butyrate also plays a role in stimulating GLP-1 (a hormone produced by the gut) secretion, which helps maintain a healthy balance between insulin and glucose levels. [5, 6,8, 9, 24-30]
*Figure adapted from "Alterations in Gut Microbiota and Immunity by Dietary Fat", Yonsei Medical Journal 58(6):1083, November 2017. https://www.researchgate.net/publication/320492093_Alterations_in_Gut_Microbiota_and_Immunity_by_Dietary_Fat
Butyrate signals to the immune system when immune defenses need to ramp up. When there is not enough butyrate production in the microbiome, the immune system is compromised.
Mucin protects your gut lining (and ultimately the immune system). PGC contains novel strain Akkermansia muciniphila, which has been shown in 3rd party research to help modulate the gut lining. People with type 2 diabetes are shown to have lower levels of Akkermansia and gut lining modulation. A strong gut lining is vital to ensure that small molecules in the gut don't “leak” across the gut lining into the bloodstream, which can cause heightened inflammation and compromise the immune system. [33-34]
Our patented formula contains 5 targeted strains of probiotics (beneficial bacteria) and a prebiotic (food to fuel bacteria).
Akkermansia muciniphila WB-STR-0001 (gut lining probiotic)
A unique and novel bacterial strain that can only be found in PGC. This strain was first identified by Dr. Lee Kaplan, Associate Professor of Medicine at Harvard School of Medicine and Director of the Obesity, Metabolism and Nutrition Institute. Over 800 studies have been published on Akkermansia muciniphila and have shown that many people with diabetes and heightened inflammation have lower amounts than healthy people. Akkermansia muciniphila is naturally found in your gastrointestinal (GI) tract, where it directly interacts with the gut lining and helps regulate the mucus lining of the gut. This strain also helps maintain a healthy ecosystem of beneficial bacteria in the GI. [11, 12, 16, 33]
Eubacterium hallii WB-STR-0008 (butyrate-producing probiotic)
A unique and novel bacterial strain that can only be found in PGC. Many studies have shown that people with diabetes and prediabetes are low in or entirely missing this strain, whereas healthy people have it in vast abundance in their guts. This strain is an important microbe for intestinal metabolic balance due to its ability to utilize glucose to form butyrate. 
Clostridium butyricum WB-STR-0006 (digestive and immune health probiotic)
Naturally found in the human gut microbiome, this strain is named for its ability to produce high amounts of butyrate. It's been clinically shown to support healthy gut microflora, digestion and immune health. It's also been shown to help relieve irritable bowel syndrome (IBS) symptoms including reducing abdominal pain, gas and bloating. [17-19]
Clostridium beijerinckii WB-STR-0005 (butyrate-producing probiotic)
Naturally found in the human GI tract, this strain produces butyrate. 
Bifidobacterium infantis 100 (digestive health probiotic)
A common bacterial strain naturally found in the human oral cavity and GI tract. This strain helps maintain a healthy digestive tract and has been shown to help relieve IBS symptoms including reducing abdominal pain, gas and bloating. [20, 21]
Inulin (healthy blood sugar prebiotic)
A soluble fiber sourced from chicory root. Inulin is classified as a prebiotic because of its ability to travel to the lower gut and stimulate the growth of beneficial bacteria, including the bacterial strains in our product. Studies have shown supplementation with inulin helps lower fasting blood sugar, reduce fasting insulin, and improve "good" (HDL) cholesterol in people with T2D. [22, 23]
Our medical research team is led by Chief Medical Officer, Orville Kolterman, M.D., a well-respected diabetes expert based on his contributions to diabetes drug development and the diabetes community. Dr. Kolterman was previously the Chief Medical Officer at Amylin Pharmaceuticals, where he successfully brought four diabetes drugs from early-stage development through trials and to market.
Together with Dr. Kolterman, we work with leading diabetes professionals to ensure that our products deliver exceptional results and meet the highest standards of efficacy and safety.
Dr. Kolterman received his MD from Stanford University School of Medicine, performed his residency in Internal Medicine at the University of Chicago and Endocrinology training at Stanford University.
Dean for Precision Medicine, Icahn School of Medicine at Mount Sinai.
Associate Professor of Integrative Functional Genomics, Clinical Genetics and Synthetic Biology at Weill Cornell Medical College.
Professor in Civil and Environmental Engineering at Stanford University.
Team Leader at the French National Institute for Agricultural Research.
Professor and Chair of the Department of Human Genetics at the University of Pittsburgh Graduate School of Public Health.
Assistant Professor of Department of Microbiology and Immunology for G.W. Hooper Research Foundation at University of California, San Francisco.
Verne S. Caviness Distinguished Professor, Chief of the Division of Endocrinology, Director of the Diabetes Center, Director of the NC Translational and Clinical Sciences Institute and Executive Associate Dean for Clinical Research at the University of North Carolina (UNC) School of Medicine in Chapel Hill.
Clinical Professor of Medicine at the University of Washington School of Medicine and is Clinical Endocrinologist at Rockwood Multicare Center for Diabetes and Endocrinology in Spokane, Washington.
Gastroenterologist, Neuroscientist and Professor in the Departments of Medicine, Physiology and Psychiatry at the David Geffen School of Medicine at UCLA.
Director of the Johns Hopkins Center for Neurogastroenterology, Professor of Medicine and Vice Chair of Medicine Innovation and Commercialization.
Professor of Clinical Medicine at the Keck School of Medicine of the University of Southern California and Director of the USC Clinical Diabetes Programs.
Former Chief Scientific & Medical Officer for the American Diabetes Association.
Certified Nurse Practitioner in diabetes at Henry Ford Health System.